Can Escalation Reduce Acute Myocardial Infarction Mortality in Cardiogenic Shock (NCT05800951) | Clinical Trial Compass
Active — Not RecruitingNot Applicable
Can Escalation Reduce Acute Myocardial Infarction Mortality in Cardiogenic Shock
United States124 participantsStarted 2022-07-22
Plain-language summary
The CERAMICS study is designed to more clearly delineate the current care of acute myocardial infarction with cardiogenic shock (AMICS) patients who are treated with mechanical circulatory support (MCS) devices in the United States with significant experience in MCS, all of whom have the capability of MCS escalation on-site. Study enrollment is targeted at 120 patients at 20 hospital sites, evaluating clinical outcomes, and focusing on outcomes MCS escalation decision making and ICU level management.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Diagnosis of acute AMI confirmed by a medical professional, with changes in serum biomarkers or evidence of ischemic EKG changes (STEMI or NSTEMI).
. Cardiogenic Shock present as defined by the presence of 2 OR MORE of the following criteria prior to PCI:
. Patient underwent PCI within 12 hours of hospital presentation.
Exclusion criteria
. Evidence of Anoxic Brain Injury
. Unwitnessed out of hospital cardiac arrest or any cardiac arrest in which return of spontaneous circulation (ROSC) is not achieved within 30 minutes
. IABP placed prior to MCS
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Since this trial is focused on cardiogenic shock complicating a heart attack, can you explain whether my specific situation — including whether I had a STEMI or NSTEMI — would be relevant to what this study was testing?
2This trial is listed as 'active but not recruiting,' which means they're no longer enrolling new patients — does that change what options are available to me, and could the results from this study still influence how you'd approach my treatment?
3The trial's main goal was to measure survival at hospital discharge and at 30 days — based on what's been observed so far, is there anything from this research that might inform the decisions being made about my care right now?
4Cardiogenic shock is a life-threatening emergency — can you walk me through what 'escalation' of treatment actually means in practice, and how aggressively you'd consider pursuing that approach in my case compared to standard care?
5Are there other ongoing trials or established treatment protocols for cardiogenic shock after a heart attack that you think might be a better fit for my situation than waiting for published results from this study?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Hospital discharge survival/survival at 30 days
Timeframe: Hospital discharge survival/survival at 30 days